Biogen News and Research

RSS

Researchers identify genes linked to most severe symptoms of multiple sclerosis

In a bid to determine factors linked to the most debilitating forms of multiple sclerosis, Johns Hopkins Medicine researchers say they have identified three so-called "complement system" genes that appear to play a role in MS-caused vision loss.

From Johns Hopkins Medicine 31 Oct 2019

Risk factors for unemployment with multiple sclerosis vary by age, study finds

A recent study by Kessler Foundation researchers explored numerous factors that contribute to the high unemployment rate among individuals of different ages with multiple sclerosis.

24 Oct 2019

Biogen to pursue FDA regulatory approval for investigational drug aducanumab

On behalf of the more than 5 million Americans living with Alzheimer's and their family members, the Alzheimer's Association is encouraged to learn that Biogen will pursue regulatory approval from the FDA for the investigational drug aducanumab based on Phase 3 clinical trial results from the EMERGE and ENGAGE studies, and other related data, after finding a reduction of cognitive and functional decline in people taking the high dose.

22 Oct 2019

Kessler researchers awarded grant to study effects of exercise in patients with MS

With a grant from the Consortium of Multiple Sclerosis Centers, John DeLuca, PhD, Helen Genova, PhD, of Kessler Foundation, will study the effects of different exercise regimens across multiple realms of symptoms and functioning in individuals with multiple sclerosis.

7 Oct 2019

Experts call for public health campaign aimed at promoting 'brain-healthy lifestyle'

Experts are calling for a public health campaign aimed at promoting a 'brain-healthy lifestyle' to reduce the risk of developing neurodegenerative brain diseases, such as Alzheimer's disease and Parkinson's disease.

4 Oct 2019

Scientists move one step closer to discovering the causes of immune diseases

Scientists are one step closer to discovering the causes of immune diseases such as asthma, multiple sclerosis and arthritis

23 Sep 2019

Scientists link neuropsychological tests with real-life activity in MS patients

A recent review by Kessler Foundation researchers explored the relationship between neuropsychological assessment and predictability of performance of everyday life activities among people with multiple sclerosis (MS).

20 Sep 2019

Quanterix Serum Nf-L assay powers key trial and study results presented at ECTRIMS 2019

Quanterix, announce that its Simoa technology and Nf-L assays were used in many of the groundbreaking research and treatment developments.

From Quanterix 18 Sep 2019

World Alzheimer’s Day 2019: A timely reminder of urgent need for new drugs to tackle disease

As World Alzheimer’s Day 2019 approaches (21 September), with the aim this year of raising global awareness and understanding of the stigma, stereotypes and myths that surround a dementia diagnosis;

17 Sep 2019

Study investigates link between social cognition and fatigue, mood in multiple sclerosis

A recent study by Kessler Foundation researchers linked the deficits in social cognition in multiple sclerosis with symptoms in other domains.

29 Aug 2019

Discover the latest advances in neuromuscular therapeutics at NMD 2019

The 2nd Neuromuscular Drug Development Summit, or NMD, will be held in Boston, MA, from October 23-25,2019.

From Hanson Wade 19 Aug 2019

Abnormal blood pressure in middle age and late life increases dementia risk

In a study that spanned two and a half decades and looked at data from more than 4,700 participants, Johns Hopkins researchers have added to evidence that abnormal blood pressure in midlife persisting into late life increases the likelihood of developing dementia.

14 Aug 2019

Evidence shows ketamine is not opioid and can treat depression easily

Ketamine’s reputation as an antidepressant is restored; it’s not an opioid.

From Johns Hopkins Medicine 1 Aug 2019

Don't Miss the Blood-Brain Barrier Drug Delivery (B3DD) Summit this August

The B3DD Summit will be held in Boston from August 13-15, 2019. This news story provides an overview of what you can expect at this year's conference.

From Blood-Brain Barrier Delivery Summit (B3DD) 17 Jul 2019

Novel imaging molecule reveals brain changes linked to progressive MS

Secondary progressive multiple sclerosis is a relentless disease. Over time, patients experience worsening physical, mental and mood-related symptoms.

2 Jul 2019

Nature of social cognitive deficits in people with progressive multiple sclerosis

A recent study by Kessler Foundation researchers provided new findings about the nature of social cognitive deficits in the population with progressive multiple sclerosis

26 Jun 2019

Smarter, more educated people get a cognitive 'head start', but aren't protected from Alzheimer's

In a search for clues to what may delay or prevent Alzheimer's disease, Johns Hopkins Medicine scientists report that smarter, more educated people aren't protected from the disease, but do get a cognitive "head start" that may keep their minds functioning better temporarily.

From Johns Hopkins Medicine 11 Jun 2019

CRISPR uncovers which gene fusions are critical for growth of cancer cells

In the first large-scale analysis of cancer gene fusions, which result from the merging of two previously separate genes, researchers at the Wellcome Sanger Institute, EMBL-EBI, Open Targets, GSK and their collaborators have used CRISPR to uncover which gene fusions are critical for the growth of cancer cells.

16 May 2019

Neuroscientists propose new theory about amyloid precursor protein connection in Alzheimer's

Worldwide, 50 million people are living with Alzheimer's disease and other dementias. According to the Alzheimer's Association, every 65 seconds someone in the United States develops this disease, which causes problems with memory, thinking and behavior.

23 Apr 2019

National Multiple Sclerosis Society awards grant for pilot study of social interaction in individuals with MS

Ekaterina Dobryakova, PhD, and Pei-Pei Liu, PhD, were awarded a $50,000 grant from the National Multiple Sclerosis Society to conduct a novel study of outcome processing in individuals with MS.

26 Feb 2019